阿普米司特治疗银屑病关节炎的达标治疗:目标达成概率与疾病表现全面控制
该研究汇总三项长期评估研究,分析494例银屑病关节炎患者使用阿普米司特后第52周达到cDAPSA缓解或低疾病活动度目标的概率。基线中度疾病活动患者达标率46.9%,高疾病活动患者24.9%。第16周部分改善与达标相关,达标者关节炎及其他表现轻微。
要点
- 基线中度活动患者第52周达标率46.9%,高于高活动患者的24.9%。
- 第16周cDAPSA降低≥30%与第52周达标相关。
- 第52周达标者关节炎及其他银屑病关节炎表现轻微或无。
核心结论
- 基线中度疾病活动患者第52周达到cDAPSA缓解或低疾病活动度的概率高于高疾病活动患者。
研究设计与样本
- 汇总银屑病关节炎临床疗效长期评估研究1、2和3的事后分析,共494例患者纳入概率分析。
主要发现
- 基线中度疾病活动患者中46.9%在第52周达到治疗目标,高疾病活动患者中24.9%达到目标。
- 基线中度活动患者第16周cDAPSA降低≥30%与第52周达标相关。
- 第16周达到缓解或低疾病活动度的患者第52周维持达标的概率高。
- 375例第52周有cDAPSA组分数据的患者中,达标与疾病活动度持续改善及无或轻度关节炎和其他表现相关。
关键数值与推荐
- 治疗目标为cDAPSA缓解或低疾病活动度。
- 部分改善定义为cDAPSA降低≥30%。
临床怎么用
- 对基线中度活动的银屑病关节炎患者,阿普米司特第16周部分改善可预测第52周达标。
- 达标评估应同时关注关节炎以外的银屑病关节炎表现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The present study was undertaken to evaluate the probability of achieving the Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) treatment targets of remission or low disease activity (LDA) with apremilast based on disease activity categories and corresponding responses in arthritis and other domains of psoriatic arthritis (PsA) not included in the cDAPSA. METHODS: Pooled analyses from the Psoriatic Arthritis Long-term Assessment of Clinical Efficacy studies 1, 2, and 3 were performed. Probability analyses assessing the likelihood of achieving cDAPSA treatment targets by week 52 were performed using multiple imputation for discontinuations and missing values. Longitudinal analyses were performed in patients grouped by cDAPSA category at week 52. RESULTS: Among 494 patients in the probability analyses, 46.9% with moderate disease activity and 24.9% with high disease activity at baseline achieved treatment targets (remission or LDA) by week 52. For patients with moderate disease activity at baseline, small improvements (cDAPSA reductions ≥30%) by week 16 were associated with achieving targets. Patients achieving remission or LDA by week 16 had high probabilities of remaining at treatment targets at week 52. Of 375 patients with cDAPSA components available at week 52, achieving targets with apremilast was associated with continuous disease activity improvements and no or mild arthritis and other PsA manifestations. CONCLUSION: The probability of achieving treatment targets (remission or LDA) at week 52 was greater for patients with moderate versus high disease activity at baseline. At a mean level, partial improvements by week 16 were associated with achieving treatment targets. Patients receiving apremilast who achieved cDAPSA targets by week 52 also had no or mild arthritis or other PsA manifestations.
引用
- Mease PJ, Gladman DD, Ogdie A, et al. Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. Arthritis Care Res (Hoboken). 2020. PMID: 31909868. doi:10.1002/acr.24134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。